A share price of Supernus Pharmaceuticals Inc [SUPN] is currently trading at $51.45, up 0.18%. An important factor to consider is whether the stock is rising or falling in short-term value. The SUPN shares have gain 4.45% over the last week, with a monthly amount glided 10.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Supernus Pharmaceuticals Inc [NASDAQ: SUPN] stock has seen the most recent analyst activity on October 09, 2025, when Piper Sandler upgraded its rating to an Overweight but kept the price target unchanged to $65 for it. Previously, Cantor Fitzgerald upgraded its rating to Overweight on July 30, 2025, and kept the price target unchanged to $42. On February 19, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $36 on the stock. Cantor Fitzgerald started tracking the stock assigning an Overweight rating and suggested a price target of $57 on January 06, 2025. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $36 on September 11, 2024.
Supernus Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $29.16 and $57.65. Currently, Wall Street analysts expect the stock to reach $61 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $51.45 at the most recent close of the market. An investor can expect a potential return of 18.56% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
Trailing Twelve Months sales for Supernus Pharmaceuticals Inc [NASDAQ:SUPN] were 681.54M which represents 9.34% growth. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.31%, Pretax Profit Margin comes in at -0.3%, and Net Profit Margin reading is -0.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.0 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Supernus Pharmaceuticals Inc [NASDAQ:SUPN] is 1.80. On the other hand, the Quick Ratio is 1.56, and the Cash Ratio is 0.46. Considering the valuation of this stock, the price to sales ratio is 4.33, the price to book ratio is 2.80.
Transactions by insiders
Recent insider trading involved Mottola Frank, SVP, Chief Tech. Ops. Officer, that happened on Dec 19 ’25 when 20000.0 shares were sold. Officer, FRANK MOTTOLA completed a deal on Dec 19 ’25 to buy 20000.0 shares. Meanwhile, Sr. VP of IP, CSO Bhatt Padmanabh P. sold 710.0 shares on Dec 18 ’25.
